Email this article FTORAFUR IN COMBINATION WITH OXALIPLATIN AND IRINOTECAN IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER: PRELIMINARY RESULTS
- Authors: Dobrova N.V.1, Aratyunyan E.A.1, Polushkina I.N.1, Aliev V.A.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 7, No 4 (2017)
- Pages: 44-53
- Section: ORIGINAL REPORT
- Published: 27.02.2018
- URL: https://onco-surgery.info/jour/article/view/234
- DOI: https://doi.org/10.17650/2220-3478-2017-7-4-44-53
- ID: 234
Cite item
Full Text
Abstract
Objective: to develop an effective, well-tolerated, convenient for outpatient care (without installing a subclavian catheter) three-component treatment regimen that includes ftorafur – an original oral fluoropyrimidine drug.
Materials and methods. The study included 25 patients with disseminated colorectal cancer that have never received specific pharmacotherapy. We evaluated the efficacy and safety of a new first-line three-component treatment regimen with oxaliplatin + irinotecan + ftorafur. Patients in group 1 (n = 6) received this regimen for 3 weeks, whereas patients in group 2 (n = 19) received it for 2 weeks.
Results. Only preliminary results of the study are currently available. Median time to progression and overall survival are not yet estimated. Three (50 %) patients from group 1 achieved partial regression of metastases; 3 patients from this group had long-term (≥6 months) disease stabilization. Therapeutic effect (partial remission + long-term stabilization) was observed in all patients. Time without progression varied between 6 and 20 months. In group 2, therapeutic effect was estimated in 18 patients that received at least 2 courses of chemotherapy. Eight out of these 18 patients had partial response (2 of them underwent radical surgery); 8 patients had disease stabilization. Thus, 88.8 % of patients from group 2 responded to treatment. In the whole study population (both groups), response to treatment was achieved in 91 % of patients.
Conclusion. Our preliminary results suggest that the combination of oxaliplatin, irinotecan and ftorafur is safe and has an acceptable toxicity profile; therefore, it can be used in weakened patients.
Keywords
About the authors
N. V. Dobrova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: dobrova2008@rambler.ru
23 Kashirskoe Shosse, Moscow 115478, Russia
Russian FederationE. A. Aratyunyan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow 115478, Russia
Russian FederationI. N. Polushkina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow 115478, Russia
Russian FederationV. A. Aliev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow 115478, Russia
Russian FederationReferences
Supplementary files
